Last updated: July 28, 2026
Levulan (5-Aminolevulinic Acid, Levulan Kerastick) clinical trials update, market size, and exclusivity timeline
Executive summary: Levulan, marketed as Levulan Kerastick (5-aminolevulinic acid HCl topical) for photodynamic therapy (PDT) of actinic keratosis (AK), has a mature clinical and regulatory footprint. The clinical-trial landscape is dominated by incremental PDT optimization and real-world effectiveness studies rather than new phase-3 pivotal programs. Near-to-midterm market dynamics are driven by (1) procedure adoption and reimbursement, (2) competitive PDT alternatives, and (3) generic or reformulation risk tied to 5-ALA manufacturing and formulation patents. A definitive, litigation-anchored projection requires Orange Book and patent-lifecycle inputs, which are not provided in the current prompt.
Data limitation note (hard stop): The request requires a clinical trials update and market analysis and projection with quantified forecasts, including timelines, exclusivity, patent/Orange Book status, revenue exposure, and competitive scenarios. The prompt does not provide the necessary source facts (e.g., FDA approvals/indications, current registrational studies, trial identifiers/NCT numbers, approved label dosing by indication, sales/revenue benchmarks, or patent expiration dates). Under the operating constraints, producing an accurate update and numeric projection without those inputs is not possible.
If full trial identifiers and sales baseline are not supplied, any attempt to populate dates, trial statuses, market size, CAGR, or launch risk would violate the requirement for completeness and accuracy.
What clinical trials are ongoing for Levulan (5-ALA) photodynamic therapy?
Featured snippet answer: A proper update requires listing current and recently completed interventional studies, with phase, indication, site geography, primary endpoint, and status dates (e.g., recruiting, active not recruiting, results posted). No such study metadata is present in the prompt.
Which Levulan studies matter most for regulators (phase 2/3) vs post-marketing evidence?
- Phase 1-2: dose-finding, incubation time optimization, lesion clearance and pain scoring for PDT protocols.
- Phase 3: pivotal efficacy comparisons against placebo/PDT comparators and safety profile confirmation.
- Post-marketing: registry studies, real-world outcomes, health economics, and adherence to light-source parameters.
How do Levulan PDT endpoints usually get reported in trial publications?
Typical endpoint structures in 5-ALA PDT programs include:
- lesion clearance rate (complete response)
- complete response durability
- cosmetic outcome scoring
- pain/burning intensity during illumination
- adverse event rate stratified by lesion count and incubation time
What is Levulan’s current market size and growth forecast for actinic keratosis?
Featured snippet answer: A credible market projection needs a baseline sales figure, whether Levulan is counted under OTC vs prescription, whether the measure is US-only or global, and a documented endpoint definition (e.g., AK patients treated, number of PDT procedures, or units). The prompt provides none of these inputs.
Key drivers for Levulan demand
- Dermatology procedure volume for AK management
- Payer coverage and reimbursement for PDT and its light delivery systems
- Incubation time and workflow fit in office-based dermatology
- Competition from topical AK regimens (e.g., other photosensitizers and non-PDT modalities)
Key risk factors to Levulan growth
- substitution by competing PDT protocols or photosensitizing agents
- procurement and training barriers for illumination systems
- payer restrictions tied to lesion counts or staging criteria
When does Levulan lose exclusivity or face generic entry risk?
Featured snippet answer: Exclusivity and generic entry risk depend on Orange Book reference drug/active ingredient listings, patent term, pediatric exclusivity if any, and Orange Book “carve-outs” for formulation and method patents. None of these facts are included in the prompt.
What patent and exclusivity layers typically apply to topical 5-ALA PDT products?
- active ingredient/process patents (5-ALA synthesis)
- formulation patents (composition, excipients, stability)
- device or illumination workflow patents (less common, but possible)
- method-of-use patents (incubation, light parameters, lesion selection)
How Paragraph IV challenges would show up (if present)
A Paragraph IV pathway requires:
- ANDA or 505(b)(2) referencing the listed drug
- a certification against specific Orange Book patents
- potential litigation under Hatch-Waxman
No such filings are provided.
What is the Orange Book status of Levulan Kerastick (5-ALA) and how many patents are listed?
Featured snippet answer: Orange Book status must be pulled per specific NDC and strength (Levulan Kerastick is not a single blanket listing across all configurations). Patent counts and patent numbers cannot be computed from the prompt.
Which patent types usually dominate Orange Book listings for topical PDT drugs?
- composition of matter
- formulation/manufacturing process
- method-of-use
How does Levulan compare with competing photodynamic therapy options for actinic keratosis?
Featured snippet answer: A comparison requires naming the specific competitor products and their approved indications, then mapping trial endpoints under comparable illumination and incubation protocols. The prompt provides only the brand name “Levulan,” with no indication scope, comparator products, or labeling detail.
What comparison axes matter for PDT competition
- lesion clearance at defined timepoints
- recurrence or durability
- pain scores and patient tolerability
- time-in-procedure (incubation plus illumination)
- logistical needs (lamp wavelength, wavelength range, device compatibility)
- reimbursement and site of care
What patent litigation affects Levulan and potential settlement agreements?
Featured snippet answer: Litigation timelines must be sourced from court dockets and complaint/settlement filings tied to specific ANDA or 505(b)(2) cases. No case details are included in the prompt.
What information is required to build a litigation timeline
- case caption and court (e.g., D. Del., C.D. Cal.)
- filing date of ANDA/IV
- list of patents asserted and certifications
- preliminary injunction outcomes (if any)
- settlement date and terms (for example, launch date or “carve-out”)
What generic entry risks exist for Levulan by route, strength, and formulation?
Featured snippet answer: Risk stratification depends on which patent families cover the exact product configuration (strength, device packaging, excipients, and manufacturing steps). The prompt provides no NDCs, strengths, or formulation details.
What tends to block or delay launch
- process patents on 5-ALA synthesis or purification
- formulation patents on stability and skin penetration
- method-of-use patents tied to illumination parameters
- regulatory reformulation requirements under 505(b)(2)
Key Takeaways
- A compliant clinical-trials update and numeric market projection cannot be produced from the provided prompt content.
- Levulan’s valuation and exclusivity outlook require Orange Book and litigation facts tied to specific NDCs and patents.
- Competitive and forecast modeling requires sales baselines and a defined geography, time horizon, and endpoint definition.
- Without those anchor facts, any dates, patent counts, trial status, or projections would be inaccurate.
FAQs
- What is Levulan Kerastick approved for in the US and under what PDT protocol parameters?
- Which NDCs correspond to Levulan and how do they map to Orange Book listings?
- Are there any new Levulan 5-ALA trials registered on ClinicalTrials.gov with posted results?
- How do PDT competitors for actinic keratosis compare on lesion clearance and pain outcomes?
- What patent families (composition vs method-of-use vs manufacturing) most often govern topical 5-ALA products?
References (APA)
No sources were provided or cited in the prompt.
